4th International HIV/Viral Hepatitis Co-Infection Meeting
The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings
22-23 July 2017 | Paris, France

The 4th International HIV/Viral Hepatitis Co-Infection Meeting is organized by the International AIDS Society (IAS) and will take place prior to the 9th IAS Conference on HIV Science (IAS 2017) at the Campus des Cordeliers, Université Pierre et Marie-Curie (UPMC) in Paris, France.

Building on the previous three successful annual meetings, the 4th International HIV/Viral Hepatitis Co-Infection Meeting will provide a unique opportunity to bring together a diversity of scientific, technical and community interests to discuss current opportunities and challenges for increased prevention, diagnosis and treatment of viral hepatitis in people living with HIV. While the focus of the 3rd International HIV/Viral Hepatitis Co-Infection Meeting was on medical and access challenges in low- and middle-income settings in particular, the 4th meeting will also take advantage of the meeting location to explore the reality faced by people co-infected with HIV and viral hepatitis in high-income countries and across Eastern Europe and Central Asia. It will also be an opportunity to take stock of some of the scientific breakthroughs and brainstorm on concrete actions to support the WHO targets in their sector strategies.

The meeting will focus on addressing the challenges of achieving elimination of hepatitis B and C in HIV-infected populations worldwide through reviewing the latest information on epidemiology, prevention, diagnostics and treatment. Furthermore, the meeting will have a particular focus on access to care and new curative treatments especially for key populations with overlapping risk for both HIV and viral hepatitis, such as people who inject drugs, prisoners and men who have sex with men. These topics will be explored through a combination of keynote presentations to provide broad and assertive overviews of the different areas, invited and abstract-based oral and poster presentations to highlight cutting-edge science, and invited panel discussions and debates, with strong community participation, to go beyond the data and address the obstacles that continue to hinder the full implementation of available diagnostic and treatment options.

Organizing Committee

Marina Klein, McGill University and CIHR Canadian HIV Trials Network, Montreal, Canada
Karine Lacombe, Hôpital Saint-Antoine, Paris, France

Monique Andersson, Stellenbosch University, Faculty of Health Sciences, Cape Town, South Africa
Isabelle Andrieux-Meyer, Drugs for Neglected Diseases initiative, Geneva, Switzerland
Sanjay Bhagani, Royal Free Hospital, London, UK
Christoph Boesecke, University of Bonn, Bonn, Germany
Laurent Castera, Hôpital Beaujon, Paris, France
Greg Dore, Kirby Institute, Sydney, Australia
Jordan Feld, University of Toronto, Toronto, Canada
Niklas Luhmann, Médecins du Monde, Paris, France
Ludmila Maistat, Alliance for Public Health, Kiev, Ukraine
Gail Matthews, Kirby Institute, Sydney, Australia
Sébastien Morin, International AIDS Society, Geneva, Switzerland
Jacques Normand, National Institute on Drug Abuse, Washington D.C., USA
Jean-Michel Pawlotsky, Henri Mondor University Hospital, Créteil, France
Marion Peters, University of California, San Francisco, USA
Lionel Piroth, CHU Dijon Bourgogne, Dijon, France
Jürgen Rockstroh, University of Bonn Bonn, Germany
Tracy Swan, Médecins Sans Frontières, New York, USA

Meeting material

  • Related documents
  • Day 1
  • Day 2
  • Posters
  • Multimedia

Marina Klein, McGill University Health Centre, Canada

Presentation | Webcast

Welcome to France: Update on the role of community research for hepatitis prevention
Patrizia Carrieri, INSERM, France

Presentation | Webcast

Taking Stock

Update on global epidemiology/elimination targets: Are we on track?
Gottfried Hirnschall, WHO, Switzerland

Presentation | Webcast

Emerging epidemics: Will they derail progress? (Eastern/Central Europe)
Marieta Simonova, Clinic of Gastroenterology, Military Medical Academy, Bulgaria

Presentation | Webcast

Emerging epidemics: Will they derail progress? (Rural HIV-HCV related epidemics in the USA)
John T. Brooks, CDC, United States

Presentation | Webcast

Where are we now on priorities identified at Durban?
Monique Andersson, University of Oxford NHS Foundation Trust, UK and University of Stellenbosch, South Africa

Presentation | Webcast

Q&A with all session speakers


New diagnostics: Point of care testing for HCV
Jordan Feld, Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health, University of Toronto, Canada

Presentation | Webcast

The evolution in HBV markers
Slim Fourati, Groupe hospitalier Henri Mondor, France

Presentation | Webcast

Approaches for simplified diagnostic/screening algorithms
Niklas Luhmann, Médecins du Monde, France

Presentation | Webcast

Q&A with all session speakers

Linkage to care: Different strokes for different folks?

People who inject drugs
Margaret Hellard, Burnet Institute, Alfred Hospital, Australia

Presentation | Webcast

Rick Altice, Yale University, United States

Presentation | Webcast

Men who have sex with men
Andri Rauch, University Hospital Bern, Switzerland

Presentation | Webcast

Community-driven programmes
Anton Basenko, Alliance for Public Health, Ukraine

Presentation | Webcast

Q&A with all session speakers


Treatment guidelines update
Alessio Aghemo, Università degli Studi di Milano, Italy

Presentation | Webcast

Shorter durations and pan-genotypic regimens: The final frontier?
Greg Dore, Kirby Institute, Australia

Presentation | Webcast

HCV treatment in active PWID: Is there a concern about reinfection?
Jason Grebely, Kirby Institute, Australia

Presentation | Webcast

What do clinicians need to watch for with DAA therapy?
Jürgen Rockstroh, University Hospital Bonn, Germany

Presentation | Webcast

Case discussion 1
Sanjay Bhagani, Royal Free Hospital/UCL, United Kingdom

Presentation | Webcast

Case discussion 2
Lionel Piroth

Presentation | Webcast

Q&A with all session speakers

Bringing it together: The scale up

Is elimination possible and what will it take to achieve it?
Natasha Martin, University of California San Diego, United States

Presentation | Webcast

Test and treat: Dutch MSM treatment experience
Bart J.A. Rijnders, Erasmus MC, Netherlands

Presentation | Webcast

Economics and sustainability: The role of generics
Andrew Hill, University of Liverpool, United Kingdom

Presentation | Webcast

Access in High income countries: The European landscape
Jeffrey Lazarus, University of Barcelona, Spain

Presentation | Webcast

Community experience with expanded access
Pascal Mélin, SOS Hépatites Fédération, France

Presentation | Webcast

Q&A with all session speakers

Looking to the future

Research gaps in viral hepatitis
Jean-Michel Pawlotsky, Henri Mondor Hospital, France

Presentation | Webcast

HAV outbreak in Europe
Anne-Marie Rique-Afonso, Hôpital Paul Brousse, France

Presentation | Webcast

Panel discussion: Priorities for enhancing access and how to achieve them

Global state of HCV treatment access
Tracy Swan

Presentation | Webcast

Panel discussion

Webcast for entire panel discussion

Isabelle Andrieux-Meyer, DNDi, Switzerland

Anton Basenko, Alliance for Public Health, Ukraine

James Freeman

Céline Grillon, Médecins du Monde, France

Othoman Mellouk, ITPC

Luís Mendão, European AIDS Treatment Group


Meeting summary
Karine Lacombe, Saint-Antoine Hospital, France

Presentation | Webcast

Moving forward to address HIV co-infections and co-morbidities
Anton Pozniak, St Stephen’s Centre, Chelsea & Westminster NHS Trust, United Kingdom

Presentation | Webcast


Assessment of Prevalence of HIV, Hepatitis C, HIV/Hepatitis C co-infection and risk behaviours among Female Injecting Drug Users in Nepal
J. Damas, K. Deuba, U. Shrestha, B. Rawal, T. Paudel, G. Marrone

Burden of infectious diseases and substance abuse among incarcerated women in Kuala Lumpur, Malaysia
V. Pillai, C. Pedersen, J. Wickersham, F. Altice, A. Kamarulzaman

Chronic hepatitis C and HIV co-infection among people who inject drugs along the Kenyan Coast
R.N. Shah, J. Kinyua, A. Kattammaiyo, K. Mandaliya, B. Langat, S. Bhagani, M. Thursz, E. Songok, M. Lemoine

Countrywide epidemiology of B, C and Delta hepatitis in Burkina Faso: the ANRS 12270 clustered cross-sectional study
N. Meda, E. Tuaillon, D. Kania, A. Kiendrebeogo, A. Pisoni, S. Zida, K. Bollore, I. Meda, D. Laureillard, J.P. Moles, N. Nagot, Y. Nebie, P. Vande Perre, P.F. Dujols

Crystal Methamphetamine Initiation Among HIV-Positive and HIV-Negative Men Who Have Sex With Men in Vancouver, Canada: A Longitudinal Analysis
N.J. Lachowsky, M. Hull, Z. Cui, J. Zhu, H. Armstrong, M. Taylor, J. Edwards, G. Olarewaju, R. Hogg, E.A. Roth, D.M. Moore, Momentum Health Study

Estimated Hepatitis C Prevalence and Key Population Sizes in San Francisco: A Foundation for Elimination
S. Facente, H.F. Raymond, K. Burk, E.L. Murphy, A. Mirzazadeh, M.D. Morris, A.A. Smith, M.A. Sanchez, J.L. Evans, A. Nishimura, E. Grebe, End Hep C SF

HCV genotype profile in Brazil among HIV infected and uninfected individuals: a survey truly representative of an entire country
M. Nutini, J. Hunter, A.F. Pires, I. Kohiyama, M. Camargo, M.C. Sucupira, D. Ricardo

Hepatitis E virus serological and molecular testing in 1979 patients followed-up in 2014-2016 in HIV reference centers of university hospitals of Marseille, southeastern France
P. Colson, C. Dhiver, H. Tissot-Dupont, S. Mokhtari, A. Motte, I. Ravaux, C. Toméi, C. Tamalet, S. Aherfi, P. Brouqui, A. Stein, A. Menard

Predictors and incidence of sexually transmitted Hepatitis C virus infection in HIV positive men who have sex with men
N.A. Medland, C. Eric P F, C.S. Bradshaw, T.H.R. Read, J.J. Sasadeuz, C.K. Fairley

Predictors of HCV Seroconversion in People Who Inject Drugs in 5 Regions of Ukraine
A. Meteliuk, A. Mazhnaya, S. Filippovych, F.L. Altice

Prevalence and risk factors associated with HIV/viral hepatitis B and C co-infections among People Who Inject Drugs in Mozambique, 2013-2014
C.A. Semá Baltazar, M. Boothe, I. Sathane, E. Fazito, R. Horth, N. Bhatt

Recent incarceration and risk of hepatitis C and HIV transmission amongst people who inject drugs: A systematic review and meta-analysis
J. Stone, M. Hickman, A. Lim, H. Fraser, J. Walker, L. MacGregor, A. Trickey, S. Abbott, Z. Ward, N.K. Martin, P. Vickerman

Trends in Cause-Specific Mortality in HIV-hepatitis C (HCV) Co-infected Patients in Canada (2003 - 2016): Early Impact of HCV Therapy
N. Kronfli, S.R. Bhatnagar, M. Hull, E. Moodie, C. Cooper, N. Pick, S. Walmsley, M.-L. Vachon, V. Martel-Leferriere, J. Gill, M. Klein, on behalf of the Canadian Co-Infection Cohort Investigators


Circulating Mucosal associated invariant T cells (MAITs) fail to be recovered by successful direct-acting antiviral therapy (DAA) in HIV/HCV co-infected patients
E.S. Cannizzo, M. Cerrone, E. Merlini, B. van Wilgenburg, L. Swadling, C. Tincati, A. De Bona, A. d'Arminio Monforte, P. Klenerman, G. Marchetti

Untreated HCV-coinfection in HIV-infected patients induces additional CD4+ T-lymphocyte deficiency due to mobilization of naive cells into immune response resulting in their regeneration failure
K. Shmagel, E. Saidakova, L. Korolevskaya, N. Shmagel, V. Chereshnev


Chronic hepatitis C among intravenous drug users in Tanzania: assessment of the liver disease and utility of HCV core antigen detection and quantification
Z. Mohamed, J. Mbwambo, Y. Shimakawa, L. Poiteau, S. Chevaliez, J.-M. Pawlotsky, J. Rwegasha, S. Bhagani, S. Taylor-Robinson, J. Makani, M. Thursz, M. Lemoine

Comparison of two Immunoassays for Simultaneous Detection of HCV Antigen and Antibodies among HCV/HIV Co-infected Patients in Dried Serum Spots
A. Eshetu, B. Bartmeyer, V. Bremer, D. Schmidt, C.-T. Bock, N. Bannert, A. Hauser

Countrywide epidemiology of B, C and Delta hepatitis in Burkina Faso: the ANRS 12270 clustered cross-sectional study
N. Meda, E. Tuaillon, D. Kania, A. Kiendrebeogo, A. Pisoni, S. Zida, K. Bollore, I. Meda, D. Laureillard, J.P. Moles, N. Nagot, Y. Nebie, P. Vande Perre, P.F. Dujols

Usual APRI score thresholds lack sensitivity to prioritize for Hepatitis C treatment in a HCV/HIV coinfected cohort in Cambodia
A. De Weggheleire, S. An, J. Buyze, S. Thai, S. Francque, L. Lynen

Validation and scale-up of Hepatitis B viral load on polyvalent open PCR platforms in West African and South East Asian countries. A study of the AC12 working group (ANRS 12327)
D. Kania, F. Rouet, K. Bolloré, J. Nouhin, R. Njouom, T.D. Toni, A. Maiga, C. Toure-Kane, N. Ngo-Giang-Huong, A. Dagnra, D.H.C. Le, F. Lunel-Fabiani, M.-L. Chaix, J. Castéra-Guy, J.-M. Da Costa Castro, C. Rouzioux, J.-C. Plantier, E. Tuaillon

Linkage to care

Hepatitis C care cascade for people living with HIV in the country of Georgia
N. Chkhartishvili, A. Abutidze, N. Bolokadze, O. Chokoshvili, N. Dvali, L. Sharvadze, T. Tsertsvadze

Integrated Surveillance for HIV, Syphilis, HBV & HCV in pregnant women attending ANC Sentinel Surveillance Sites in Eritrea, 2016
A.B. Mesfin, H. Ahmed, M. Asrat, T. Asfaha, N. Tesfamichael


Alanine aminotransferase level monitoring to detection hepatitis B virus reactivation in 170 HIV/hepatitis C virus-infected patients on direct-acting agent-based therapies
P. Colson, S. Mokhtari, H. Tissot-Dupont, C. Dhiver, I. Ravaux, L. Meddeb, A. Motte, C. Tamalet, S. Aherfi, P. Brouqui, A. Stein, A. Menard

Association of uncontrolled HIV-RNA with failure to direct acting antiviral (DAA) combinations in HIV/HCV co-infected patients on antiretroviral therapy (ART) - ANRS CO13 HEPAVIH cohort
D. Salmon, C. Gilbert, J. Chas, L. Piroth, K. Lacombe, C. Katlama, P. Trimoulet, C. Solas, G. Peytavin, H. Aumaitre, L. Alric, F. Boué, P. Morlat, I. Poizot-Martin, E. Billaud, E. Rosenthal, A. Naqvi, P. Miailhes, L. Esterle, P. Carrieri, P. Sogni, F. Dabis, L. Wittkop, HEPAVIH ANRS CO13 Study Group

Chronic Hepatitis C in Human Immunodeficiency Virus infected patients: real-life treatment with new generation Direct-Acting Antivirals in a Portuguese centre
A. Silva-Pinto, R. Ruas, I. Abreu, F. Ceia, A.C. Carvalho, N. Neves, A.S. Santos, J. Soares, C. Piñeiro, R. Serrão, A. Sarmento

Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with Hepatitis C virus and Human Immunodeficiency Virus-1: the EXPoster exhibitionDITION-2 Study
J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D. Wyles, A. Luetkemeyer, R. Soto-Malave, R. Flisiak, S. Bhagani, K. Sherman, P. Ruane, J. Sasadeusz, J. Slim, Z. Zhang, T. Ng, R. Trinh, M. Sulkowski

Evolution of glomerular filtration rate in patients concomitantly treated with ledipasvir and tenofovir
M. Fabbiani, I. De Benedetto, G. Lapadula, R. Gagliardini, A. Soria, D. Moschese, A. Muscatello, M. Rossi, N. Squillace, A. Bandera, A. De Luca, S. Di Giambenedetto, A. Gori

HCV Cure for HIV-infected patients: Not so easy to achieve in routine practice
H. Laroche, C. Lions, C. Solas, P. Carrieri, O. Faucher-Zaegel, S. Bregigeon, C. Tamalet, E. Ressiot, V. Obry-Roguet, B. Canet, I. Poizot-Martin

Role of PLHIV networks in facilitating Hepatitis C cascade of care in South and South East Asia
O. Syarif

The Global Accelerator for Paediatric Formulations (GAP-f): Ensuring children have accelerated access to optimal drug formulations
S. Morin, M. Vicari, M. Watkins, L. Lewis, F. Pascual, P. Easterbrook, M. Penazzato, GAP-f partners

The road to elimination of Hepatitis C: Analysis of SVR versus new HCV infections in 91 countries
A. Hill, S. Nath, B. Simmons

Outcomes and co-morbidities

Causes of death in HIV-monoinfected and HIV/HCV-coinfected patients in Brazil, 2000-2014
M.E. Santos, R. Abrahão Ribeiro, A. Stevens, M.P. Carrieri, W. Navegantes de Araújo

Comparative Steatosis Rates by Liver Biopsy and Transient Elastography Controlled Attenuated Parameter (CAP) in Hepatitis C (HCV) and HIV/HCV Coinfection in a Large U.S. Hepatitis Clinic: Time to Take Notice
J. Martin, O. Adeyemi, K. Burke, I. Alvaraz, C. Winston, S. Markham, B. Go, G. Huhn

Coffee intake modifies the relationship between alcohol consumption and liver fibrosis in patients co-infected with HIV and hepatitis C virus (ANRS CO13-HEPAVIH cohort)
M.E. Santos, S. Rosellini, F. Marcellin, C. Protopopescu, L. Wittkop, L. Esterle, P. Morlat, D. Zucman, A. Gervais, B. Spire, F. Dabis, D. Salmon-Ceron, M.P. Carrieri, ANRS CO13-HEPAVIH Cohort Study Group

Daily cannabis use and reduced risk of severe steatosis in a population of patients co-infected with HIV and hepatitis C virus (HCV) (ANRS CO13-HEPAVIH)
S.E. Nordmann, A. VIlotitch, P. Roux, L. Esterle, B. Spire, F. Marcellin, D. Salmon-Ceron, F. Dabis, J. Chas, D. Rey, L. Wittkop, P. Sogni, P. Carrieri, ANRS CO13 HEPAVIH study group

Does the Non-Alcoholic Fatty Liver Disease (NAFLD) Score Predict Liver Fibrosis Progression after Hepatitis C Virus (HCV) Treatment in Human Immunodeficiency Virus (HIV)-HCV Co-infected Patients?
N. Kronfli, R. Nitulescu, S. Walmsley, C. Cooper, S. Haider, J. Gill, M.-L. Vachon, M. Klein, on behalf of the Canadian Co-Infection Cohort Investigators

Effects of long-term ART on total HIV DNA levels in Japanese patients with and without haemophilia+HCV
K.R. Stanoeva, A. König, A. Fukuda, Y. Kawanami, T. Kuwata, Y. Satou, S. Matsushita

Increased risk of overweightness and obesity after HCV clearance in patients co-infected with HIV and hepatitis C virus (HCV) (ANRS CO13-HEPAVIH cohort)
I. Yaya, C. Protopopescu, F. Marcellin, L. Wittkop, L. Esterle, D. Salmon-Céron, I. Poizot-Martin, E. Rosenthal, F. Bani-Sadr, S. Nordmann, M.P. Carrieri, The ANRS CO13-HEPAVIH Study Group

Occult liver cirrhosis diagnosed by transient elastography is frequent and under-monitored in HIV-infected patients: results of a large-scale screening program
A. Benmassaoud, T. Pembroke, B. Lebouche, P. Ghali, M. Deschenes, M. Klein, G. Sebastiani

Sustained virologic response (SVR) after hepatitis C virus (HCV) treatment does not lead to improved renal function in HIV/HCV coinfected patients
C. Rossi, E. Moodie, M. Hull, V. Martel-Lafferriere, M.-L. Vachon, C. Cooper, N. Pick, S. Walmsley, M. Klein, Canadian Coinfection Cohort


An economic evaluation of the integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis
L. Zhang, L. Ferradini, N. Ishikawa, J.V. Woodring, Y. Tao, M. Nagai, Y.-R. Lo

Eliminating HCV/HIV coinfection through enhanced treatment: HCV treatment in primary care is feasible and highly effective
A.L. Bowring, J.S. Doyle, J. Roney, D. Iser, J. Sasadeusz, M. O'Reilly, C. Fairley, E. Gane, H. Jennifer, G.V. Matthews, N. Medland, R. Moore, M. Prins, M. Stoové, B.-K. Tee, M. Hellard E

Expanding the Provider Base: HIV and Hepatitis C Clinical Preceptorships in New York State
N. Harris, T. Wilder, J. Steinke, R. Walsh, A. Urbina

Generic treatments for HIV, HBV, HCV, TB could be mass produced for < $90 per patient
A. Hill, M. Barber, D. Gotham, J. Fortunak, A. Pozniak

Georgia's path towards HCV elimination
L. Sulaberidze, I. Chikovani, M. Uchaneishvili, N. Shengelia


HBV co-infection is associated with high one-year mortality in HIV-infected Tanzanians on ART
B. Christian, E. Fabian, L.R. Ammerman, I. Macha, C. Gawile, S. Mpangala, N. Ulenga, C. Thio, R. Murphy, C. Hawkins

Hepatitis B Virus Infection in HIV-1 Negative and Positive Pregnant Women in Botswana, Implications for HBV Vertical Transmission
T. Mbangiwa, M. Anderson, A. Needleman, P.K. Thami, M. Leteane, S. Moyo, D. Setlhare, G. Mayondi, T. Sebunya, T.W. Choga, R. Musonda, M. Essex, S. Lockman, S. Gaseitsiwe

Preliminary results of prevention of mother-to-child transmission of hepatitis B virus through treatment of mothers and vaccination of newborns at Ouagadougou, Burkina Faso
A.N. Guingane, N. Meda, R. Sombié, I. Guiraud, A. Bougouma

Photo gallery

View the photos of the meeting here


View the presentations under the “Day 1” and “Day 2 “ tabs






For information on sponsorship opportunities, please contact [email protected].